Pazzagli Laura, Abdi Lamya, Kieler Helle, Cesta Carolyn E
Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department for Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Eur J Obstet Gynecol Reprod Biol. 2020 Nov;254:271-276. doi: 10.1016/j.ejogrb.2020.09.037. Epub 2020 Sep 24.
Pregnant women who develop gestational diabetes (GDM) are more likely to deliver by caesarean section (CS). Over the last decade, the use of metformin has increased as an alternative to insulin but it's unknown how this shift in treatment has influenced the mode of delivery. Therefore, the aim of this study was to determine the association between metformin use and CS and delivery of a large-for-gestational age (LGA) infant compared to insulin use for GDM.
The Swedish population health registers were linked to identify pregnant women from 2012 to 2016 without preexisting diabetes and with a first filled prescription of insulin or metformin in trimester 2 or 3 (n = 2467), categorized into those treated with insulin only (88%), metformin only (7.6%), or both insulin and metformin (4.3%). Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Analyses were adjusted for relevant covariates and stratified by history of CS.
The proportion of women using metformin to treat GDM increased from 2.5% in 2012 to over 30% in 2016. Comparing insulin only to metformin only use, no association with delivery by CS (adjusted OR 0.79, 95% CI; 0.54-1.16) and lower odds of delivering a LGA infant (adjusted OR 0.44, 95% CI; 0.26-0.76) was found. Treatment with both insulin and metformin was associated with an increased risk of CS (adjusted OR 1.65, 95% CI; 1.06-2.56), which were more often unplanned. Estimates were further elevated in nulliparous (adjusted OR 2.32, 95% CI; 0.95-5.65) and multiparous women with a history of CS (adjusted OR 2.29, 95% CI; 0.60-8.74) but conclusions could not be drawn given the wide CIs.
There was no evidence of a higher association of metformin use alone with CS compared to insulin use for treatment of GDM but a protective effect for delivery of a LGA infant was shown. Women requiring treatment with both insulin and metformin had increased odds for delivery by CS which in turn may indicate that the need for the use of both medications to treat GDM suggests a pregnancy at higher risk.
患有妊娠期糖尿病(GDM)的孕妇更有可能通过剖宫产(CS)分娩。在过去十年中,二甲双胍作为胰岛素的替代品使用增加,但尚不清楚这种治疗方式的转变如何影响分娩方式。因此,本研究的目的是确定与使用胰岛素治疗GDM相比,使用二甲双胍与CS及巨大儿(LGA)分娩之间的关联。
将瑞典人口健康登记数据相链接,以识别2012年至2016年期间无糖尿病史且在孕中期或孕晚期首次开具胰岛素或二甲双胍处方的孕妇(n = 2467),分为仅接受胰岛素治疗(88%)、仅接受二甲双胍治疗(7.6%)或同时接受胰岛素和二甲双胍治疗(4.3%)的孕妇。采用逻辑回归估计比值比(OR)和95%置信区间(CI)。分析针对相关协变量进行了调整,并按CS病史进行分层。
使用二甲双胍治疗GDM的女性比例从2012年的2.5%增加到2016年的超过30%。将仅使用胰岛素与仅使用二甲双胍进行比较,未发现与CS分娩相关(调整后OR为0.79,95%CI为0.54 - 1.16),且分娩LGA婴儿的几率较低(调整后OR为0.44,95%CI为0.26 - 0.76)。同时使用胰岛素和二甲双胍治疗与CS风险增加相关(调整后OR为1.65,95%CI为1.06 - 2.56),且更多为非计划剖宫产。在初产妇(调整后OR为2.32,95%CI为0.95 - 5.65)和有CS病史的经产妇(调整后OR为2.29,95%CI为0.60 - 8.74)中,估计值进一步升高,但由于置信区间较宽,无法得出结论。
与使用胰岛素治疗GDM相比,没有证据表明单独使用二甲双胍与CS的关联更高,但显示出对LGA婴儿分娩有保护作用。需要同时使用胰岛素和二甲双胍治疗的女性CS分娩几率增加,这反过来可能表明需要使用两种药物治疗GDM提示妊娠风险更高。